Daily BriefsMost Read

Most Read: China Merchants Expressway Net, JD.com , Alibaba Group Holding , APT Medical , Shinva Medical Instrument A, Shenyang Xingqi Pharmaceutical, Eoflow, ESR Group , Li Auto , Yichang HEC Changjiang Pharma and more

In today’s briefing:

  • CSI300 Index Rebalance Preview: Bounce in the Potential Deletes Could Be Short Lived
  • HSTECH Index Rebalance Preview: Round-Trip Trade of US$2.4bn in June
  • Alibaba (9988 HK): Dual Primary Listing & Potential Southbound Flows
  • CSI500 Index Rebalance Preview: Potential Adds Rally and Outperform the Potential Deletes
  • CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains
  • ChiNext/​​​ChiNext50 Index Rebalance Preview: Outperformance Continues
  • Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps
  • (Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market
  • HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way
  • Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid


CSI300 Index Rebalance Preview: Bounce in the Potential Deletes Could Be Short Lived

By Brian Freitas

  • The review period for the June rebalance is complete and we expect 11 changes to the Shanghai Shenzhen CSI 300 Inde (SHSZ300 INDEX)
  • We estimate one-way turnover of 1.4% at the rebalance leading to a one-way trade of CNY 8.82bn (US$1.22bn). There are a lot of stocks with multiple days ADV to trade.
  • The potential deletes have bounced off their lows as the market has recovered. But the potential passive selling could see them underperform over the next month.

HSTECH Index Rebalance Preview: Round-Trip Trade of US$2.4bn in June

By Brian Freitas


Alibaba (9988 HK): Dual Primary Listing & Potential Southbound Flows

By Brian Freitas

  • Along with its fiscal 2024 results, Alibaba (9988 HK) announced that they were preparing for their primary listing in Hong Kong and the conversion was expected to complete by August.
  • If the conversion is completed by the end of August, Alibaba (9988 HK) could be added to Southbound Stock Connect in September and that could bring in significant flows.
  • We do not forecast any passive inflows due to the change with Alibaba Group Holding (9988 HK) capped at 8% of the HSI, HSCEI and HSTECH indices.

CSI500 Index Rebalance Preview: Potential Adds Rally and Outperform the Potential Deletes

By Brian Freitas

  • With the review period now complete, we forecast 50 changes (the maximum permitted) for the CSI Smallcap 500 Index – Shang (SH000905 INDEX) at the close on 14 June.
  • We estimate a one-way turnover of 9.3% at the rebalance resulting in a one-way trade of CNY10.88bn (US$1.5bn). The Industrials and Information Technology sectors gain at the expense of Materials.
  • The potential adds have outperformed the potential deletes by 8% over the last 3 months. There could be further outperformance over the next few weeks.

CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains

By Brian Freitas

  • The review period ended on 30 April, there are just over 2 weeks to announcement of the changes, and implementation will be done at the close on 14 June.
  • We forecast 5 potential changes for the index in June where there could be buying of 1.6-2.6x ADV on the adds and selling of 0.7-2.6x ADV on the deletes.
  • At the December 2023 rebalance, the adds outperformed the deletes in the weeks prior to announcement of the changes and then spiked post-announcement. Repeat this time?

ChiNext/​​​ChiNext50 Index Rebalance Preview: Outperformance Continues

By Brian Freitas

  • With the review period now complete, we forecast 7 changes for the ChiNext Index (SZ399006 INDEX) and 5 changes for the ChiNext 50 Index in June.
  • There are 4 stocks that could be added to both indices while some stocks will also have same way flows from CSI Smallcap 500 Index (SH000905 INDEX) trackers.
  • The potential adds have outperformed the potential deletes over the last 6 months. There has been a big move higher in the potential adds over the last few weeks.

Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps

By Douglas Kim

  • In this insight, we discuss the additional financing requirements, changed shareholding structure, and the next steps for Eoflow. 
  • Eoflow is one of the best performing stocks in the Korean stock market in the past one month as its shares have soared 249% in this period.
  • The details of the oral argument (Insulet vs Eoflow) at the U.S. Appellate Court suggest that the U.S. Appellate Court may rule in favor of Eoflow.

(Mostly) Asia-Pac M&A: ESR Group, I’Rom Group, S Line, Huafa Property Services, Kansai Super Market

By David Blennerhassett


HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way

By Travis Lundy

  • The Hang Seng Tech Index is more widely-followed than many think, and it is reasonably concentrated, so outperformance and underperformance by big names means capping and re-capping.
  • This time, those flows are worth about 8% of the index in terms of one-way flows. Meituan, Xiaomi, JD.com, Tencent and Kuaishou Tech DOWN. Li Auto back up. 
  • Those who have pre-positioned on the big buy have recently gotten hurt. There are some FAF changes which are less predictable and may be interesting.

Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

By David Blennerhassett

  • A “Privatisation via a Merger by Absorption” is nothing new in Hong Kong. But the Offer consideration for Yichang HEC (1558 HK)‘s minorities is in unlisted scrip – that’s new. 
  • The Offeror holds 51.41% in Yichang HEC. Founder Guo Meilan and her son Zhang Yushuai control 62.12% of the Offeror. Yichang HEC shareholders are being offered 0.263614 “Offeror H shares”.
  • These consideration shares are unlisted. An independent valuer backs out an implied scrip value of HK$18.12-HK$20.60/share. This is a super complicated, overwrought deal. With numerous unknowns. I’d vote this down. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars